Proposed Re-evaluation Decision PRVD2020-11, (S)-kinoprene and its Associated End-Use Products

Notice to the reader:

The online consultation is now closed.

Pest Management Regulatory Agency
6 August 2020
ISSN: 1925-0967 (PDF version)
Catalogue number: H113-27/2020-11E-PDF (PDF version)

If you would like to comment, please request the full consultation document.

To obtain a full copy of Proposed Re-evaluation Decision PRVD2020-11, (S)-kinoprene and its Associated End-Use Products please contact our publications office.

Should you require further information please contact the Pest Management Information Service.

Table of contents

Re-evaluation of (S)-kinoprene

Under the authority of the Pest Control Products Act, all registered pesticides must be regularly re-evaluated by Health Canada's Pest Management Regulatory Agency (PMRA) to ensure that they continue to meet current health and environmental safety standards and continue to have value. The re-evaluation considers data and information from pesticide manufacturers, published scientific reports, and other regulatory agencies. Health Canada applies internationally accepted risk assessment methods as well as current risk management approaches and policies.

(S)-kinoprene is an insect juvenile hormone analogue that inhibits insect growth during the moulting process. It is used to control aphids and whiteflies, and suppress mealybugs on greenhouse ornamental plants. It is applied as a foliar spray. Currently registered products containing (S)-kinoprene can be found in Appendix I.

This document (Proposed Re-evaluation Decision PRVD2020-11, (S)-kinoprene and its Associated End-Use Products) presents the proposed regulatory decision for the re-evaluation of (S)-kinoprene including the proposed risk mitigation measures to further protect human health and the environment, as well as the science evaluation on which the proposed decision was based. All products containing (S)-kinoprene registered in Canada are subject to this proposed re-evaluation decision. This document (PRVD2020-11) is subject to a 90-day public consultation period, during which the public including the pesticide manufacturers and stakeholders may submit written comments and additional information to PMRA Publications. The final re-evaluation decision will be published taking into consideration the comments and information received.

Outcome of science evaluation

(S)-kinoprene is an insect growth regulator. It works by contact action or ingestion, interfering with pupation, and causing sterile adults and eggs. (S)-kinoprene is valued as a tool to manage aphids, mealybugs and whiteflies in greenhouse ornamentals.

With respect to human health, risks were identified for occupational workers; risks were not shown to be acceptable when used according to current label directions, or when additional mitigation measures were considered. Therefore, cancellation of all uses for (S)-kinoprene is proposed.

(S)-kinoprene was found to present potential risks to certain terrestrial and aquatic organisms. However, potential risks to the environment from (S)-kinoprene were shown to be acceptable, with additional standard precautionary label statements to protect aquatic organisms and beneficial arthropods and with updated use directions.

Proposed regulatory decision for (S)-kinoprene

Under the authority of the Pest Control Products Act and based on an evaluation of available scientific information Health Canada is proposing cancellation of the registration of (S)-kinoprene and all associated end-use products for sale and use in Canada.

International context

(S)-kinoprene is currently acceptable for use in other Organisation for Economic Co-operation and Development (OECD) member countries including the United States. No decision by an OECD member country to prohibit all uses of (S)-kinoprene for health or environmental reasons has been identified.

Next steps

The public, including the registrants and stakeholders, are encouraged to submit comments and information on this proposed decision during the 90-day public consultation periodFootnote 1 upon publication of PRVD2020-11.

All comments received during the 90-day public consultation period will be taken into consideration in preparation of the re-evaluation decision document,Footnote 2 which could result in revised risk mitigation measures. The re-evaluation decision document will include the final re-evaluation decision, the reasons for it and a summary of comments received on the proposed re-evaluation decision with Health Canada's responses.

Additional scientific information

No additional scientific data are required at this time.

Report a problem or mistake on this page
Please select all that apply:

Thank you for your help!

You will not receive a reply. For enquiries, contact us.

Date modified: